Iron Regulation Across Reproductive Life Stages

Abstract

Iron homeostasis plays a pivotal role throughout the human lifespan, with unique regulatory challenges and clinical implications across reproductive life stages. This review synthesizes recent research on iron metabolism in pediatric, adolescent, reproductive-age, pregnant, peripartum, and postmenopausal populations, emphasizing the dynamic physiological adaptations, risk factors, and evidence-based management strategies. Special attention is paid to the mechanisms underpinning iron absorption, storage, and mobilization, as well as the clinical sequelae of iron deficiency and overload, culminating in guideline-driven recommendations for optimizing iron status in diverse patient populations.

Introduction

Iron is an essential micronutrient required for oxygen transport, cellular respiration, and DNA synthesis. Its regulation is tightly controlled to balance the risks of deficiency, which impairs erythropoiesis and cognitive function, and overload, which predisposes to oxidative damage and end-organ dysfunction. Across reproductive life stages, iron requirements and regulatory mechanisms fluctuate in response to growth, menstruation, pregnancy, lactation, and menopause. Understanding these nuanced changes is critical for clinicians managing anemia, iron overload disorders, and related pathologies in diverse patient populations.

Epidemiology / Disease Burden

Globally, iron deficiency remains the most prevalent micronutrient deficiency, affecting over 1.2 billion individuals. Adolescent girls and women of reproductive age are at heightened risk due to menstruation and increased iron demands during pregnancy. The World Health Organization estimates that 38% of pregnant women and 29% of non-pregnant women worldwide are anemic, predominantly due to iron deficiency. In contrast, postmenopausal women and older men face a rising prevalence of iron overload disorders, such as hereditary hemochromatosis. These epidemiological trends underscore the clinical importance of life stage-specific screening and intervention strategies.

Pathophysiology

Iron homeostasis is regulated by a complex interplay between dietary absorption, systemic transport, cellular storage, and utilization. The principal regulator, hepcidin, modulates intestinal iron uptake and release from macrophages and hepatocytes by binding to the iron exporter ferroportin. In reproductive-age women, menstrual blood loss is a major driver of negative iron balance. Pregnancy induces profound adaptations: maternal plasma volume expands, erythropoiesis increases, and fetal demands for iron escalate, necessitating up to a threefold increase in maternal iron absorption. Conversely, menopause attenuates cyclical iron losses, predisposing to iron accumulation over time. Genetic mutations affecting hepcidin or ferroportin may further disrupt iron regulation, contributing to inherited iron disorders.

Risk Factors

Key risk factors for iron deficiency include heavy menstrual bleeding, multiparity, short interpregnancy intervals, restrictive diets (particularly vegetarian/vegan), malabsorptive gastrointestinal disorders (e.g., celiac disease), and chronic blood loss from gastrointestinal or genitourinary sources. Iron overload risk is increased in postmenopausal women, older adults, and individuals with hereditary hemochromatosis or repeated transfusions. Socioeconomic status, access to healthcare, and underlying inflammatory conditions also modulate risk across populations.

Clinical Features

Iron deficiency manifests with nonspecific symptoms such as fatigue, pallor, dyspnea on exertion, cognitive disturbances, and restless legs syndrome. In pregnancy, iron deficiency anemia is associated with increased risk of preterm delivery, low birth weight, and impaired neurodevelopment in offspring. Iron overload may present with hepatic dysfunction, cardiomyopathy, diabetes mellitus, arthropathy, and skin hyperpigmentation, though early stages are often asymptomatic. Clinical suspicion should be guided by life stage, symptomatology, and risk profile.

Diagnosis

Laboratory evaluation should encompass hemoglobin, hematocrit, mean corpuscular volume (MCV), serum ferritin, transferrin saturation, and, in select cases, soluble transferrin receptor and hepcidin levels. Ferritin is the most sensitive marker of iron stores, with values <15 ng/mL indicating depletion. However, ferritin is an acute-phase reactant and may be elevated in inflammation or hepatic disease, necessitating contextual interpretation. In pregnancy, trimester-specific reference ranges should be applied. Genetic testing may be warranted for suspected hereditary hemochromatosis or atypical iron disorders.

Treatment & Management

Iron deficiency is managed through dietary counseling, oral iron supplementation (typically ferrous sulfate 100–200 mg elemental iron daily), and parenteral iron in cases of intolerance, malabsorption, or severe deficiency. In pregnancy, prophylactic supplementation is recommended, with therapeutic dosing adjusted for anemia severity and gestational age. Iron overload is managed by therapeutic phlebotomy or chelation therapy, guided by serum ferritin and transferrin saturation targets. Menstrual management, treatment of underlying bleeding sources, and management of comorbidities are integral to comprehensive care.

Recent Advances / Emerging Therapies

Recent advances in iron metabolism research have elucidated the central role of hepcidin in regulating systemic iron flux, paving the way for novel therapeutic targets. Hepcidin agonists and antagonists are under investigation for the management of anemia of inflammation and hereditary hemochromatosis, respectively. Oral iron formulations with enhanced bioavailability and reduced gastrointestinal side effects, such as ferric maltol and sucrosomial iron, offer promising alternatives for patients intolerant to conventional preparations. Routine implementation of point-of-care hemoglobinometry and non-invasive iron status assessment technologies may further optimize screening and monitoring.

Guideline Recommendations

International guidelines advocate routine screening for iron deficiency in high-risk populations, including pregnant women, infants, and patients with chronic diseases or heavy menstrual bleeding. The Centers for Disease Control and Prevention and the American College of Obstetricians and Gynecologists recommend universal anemia screening at the first prenatal visit and re-assessment in the second or third trimester. Prophylactic iron supplementation is endorsed for all pregnant women, with individualized dosing based on laboratory parameters. For iron overload, clinical practice guidelines support genetic screening of first-degree relatives of affected individuals and regular monitoring of serum ferritin and transferrin saturation in at-risk groups.

Conclusion

Iron regulation is a dynamic process with profound implications across the reproductive life cycle. Clinicians must recognize the shifting landscape of iron requirements and risks, employ targeted diagnostic strategies, and implement evidence-based interventions to optimize patient outcomes. Continued advances in the understanding of iron biology and therapeutic innovation hold promise for enhancing the prevention and management of iron-related disorders in diverse populations.